Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on shares of Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target on the stock.

Lipocine Price Performance

Shares of LPCN stock opened at $5.23 on Thursday. The company has a fifty day moving average price of $5.03 and a two-hundred day moving average price of $5.17. Lipocine has a one year low of $2.82 and a one year high of $11.79. The stock has a market cap of $27.97 million, a P/E ratio of -6.88 and a beta of 1.23.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, equities research analysts anticipate that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new position in Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.